leadf
logo-loader
viewVentriPoint Diagnostics Ltd.

'We have a shot at being a multi-billion dollar company', says VentriPoint Diagnostic's George Adams

Dr George Adams, CEO & president of VentriPoint Diagnostics (CVE:VPT) runs Proactive through the company's heart analysis technology and growth strategy as well as plans for 2017.

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.095 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $6.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Ventripoint Diagnostics new Director sees strong path forward updated VMS system

Ventripoint Diagnostics (CVE: VPT-OTC: VPTDF) New Director Hugh MacNaught joined Steve Darling from Proactive to discuss his new role on the board of the company. He also shares his background and what he brings to the company. MacNaught also shared details about the news VMS technology and...

1 week, 6 days ago

2 min read